-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $30

Benzinga·09/14/2026 18:03:11
语音播报
Stifel analyst Laura Prendergast maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $48 to $30.